Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast

Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntouniadakis, Eleftherios, Landström, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841725/
https://www.ncbi.nlm.nih.gov/pubmed/33568982
http://dx.doi.org/10.1159/000511697
_version_ 1783643866578026496
author Ntouniadakis, Eleftherios
Landström, Fredrik
author_facet Ntouniadakis, Eleftherios
Landström, Fredrik
author_sort Ntouniadakis, Eleftherios
collection PubMed
description Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile together with its uncomplicated follow-up and monitoring when compared to other DMARDs facilitates even a broad off-label prescribing. Here, the first case of laryngeal pseudotumor in a patient treated with apremilast for plaque psoriasis is presented.
format Online
Article
Text
id pubmed-7841725
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-78417252021-02-09 Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast Ntouniadakis, Eleftherios Landström, Fredrik Case Rep Dermatol Single Case Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile together with its uncomplicated follow-up and monitoring when compared to other DMARDs facilitates even a broad off-label prescribing. Here, the first case of laryngeal pseudotumor in a patient treated with apremilast for plaque psoriasis is presented. S. Karger AG 2020-12-16 /pmc/articles/PMC7841725/ /pubmed/33568982 http://dx.doi.org/10.1159/000511697 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Ntouniadakis, Eleftherios
Landström, Fredrik
Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title_full Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title_fullStr Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title_full_unstemmed Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title_short Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast
title_sort pseudotumor of the larynx: a previously unreported side effect of apremilast
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841725/
https://www.ncbi.nlm.nih.gov/pubmed/33568982
http://dx.doi.org/10.1159/000511697
work_keys_str_mv AT ntouniadakiseleftherios pseudotumorofthelarynxapreviouslyunreportedsideeffectofapremilast
AT landstromfredrik pseudotumorofthelarynxapreviouslyunreportedsideeffectofapremilast

Ejemplares similares